Ipsen To Set Up Its Own U.S. Oncology Team For Somatuline® Depot® (Lanreotide) Injection In Neuroendocrine Tumors
Published: Jan 14, 2014
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Euronext : IPN ; ADR : IPSEY) today announced its decision to set up its own oncology team to commercialize Somatuline® Depot® (lanreotide) 120 mg Injection (referred to as Somatuline®) in neuroendocrine tumors (NETs) in the US.
Help employers find you! Check out all the jobs and post your resume.